Previous 10 | Next 10 |
Generic drugmaker Amphastar Pharmaceuticals (NASDAQ:AMPH) announced on Monday that the FDA approved its Abbreviated New Drug Application ("ANDA") for Regadenoson, a bioequivalent and therapeutically equivalent to Lexiscan developed by Astellas Pharma (OTCPK:ALPMF) (OTCPK:ALPMY). Regadenoson i...
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 24, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New Drug Application ("ANDA") for Regadenoson injection, 0.08 mg/mL, 5mL Single Dose Pre-Filled...
Amphastar Pharmaceuticals has several key growth drivers: a strong pipeline of products currently awaiting approval, exciting products with growing sales, and growing marketing and distribution channels. With approvals for its developed products pending, AMPH could anticipate doubling...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips These seven safe small-cap stocks to buy have catalysts in play that should keep them moving higher. Amphastar Pharmaceuticals ( AMPH ): Reasonably priced play in the healthcare sector. Arcos Dorados Holdings (...
Image source: The Motley Fool. Amphastar Pharmaceuticals (NASDAQ: AMPH) Q1 2022 Earnings Call May 09, 2022 , 5:00 p.m. ET Operator Continue reading For further details see: Amphastar Pharmaceuticals (AMPH) Q1 2022 Earnings Call Transcript...
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2022 Earnings Conference Call May 09, 2022 5:00 PM ET Company Participants Dan Dischner - VP, Corporate Communications Bill Peters - CFO Conference Call Participants Elliot Wilbur - Raymond James David Amsellem - Piper Sandler Tim Chiang - Northland S...
Amphastar Pharmaceuticals press release (NASDAQ:AMPH): Q1 Non-GAAP EPS of $0.47. Revenue of $120.4M (+16.9% Y/Y). For further details see: Amphastar Pharmaceuticals Non-GAAP EPS of $0.47, revenue of $120.4M
Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended March 31, 2022. First Quar...
Healthcare historically outperforms during inflation & recession fears. Managed care, pharmaceutical, and biotech stocks have been the top performers within the sector. UnitedHealth Group, Amphastar, and Regeneron are our favorite short and long-term plays. For further d...
ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT, CAPL, CARA, CARG, CHMI, CLAR, CLOV, CNNE, CSTL, OTCPK:CURLF, DDD, DHT, DNB, ENTA, EQH, EVBG, FCRD, FF, FGEN, FLL, ...
News, Short Squeeze, Breakout and More Instantly...
Amphastar Pharmaceuticals Inc. Company Name:
AMPH Stock Symbol:
NASDAQ Market:
Amphastar Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Complete Solaria Inc Com (CSLR) rose 58.5% to $1.775 on volume of 71,457,263 shares Senti Biosciences Inc. (SNTI) rose 55.1% to $0.428 on volume of 64,207,396 shares Golden Heaven Group Holdings Ltd. (GDHG) rose 13.3% to $0.1711 on vo...
2024-06-19 18:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...